Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -228K | 0 | 0 | -235K | 0 |
| Operating Income | -48M | -54M | -51M | -44M | -29M |
| EBITDA | -48M | -34M | -26M | -21M | -11M |
| Net Income | -23M | -34M | -26M | 757K | -12M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.13
+10.78% today
1Y Change
+346.15%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cognition Therapeutics, Inc. (CGTX) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $1.13 and up 346.2% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +62.4%, free cash flow +13.7% with operating margin 0.0% and ROIC -136.9%. Stock Foundry combines CGTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CGTX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CGTX Max Drawdown
-81.29%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CGTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$11.7M
-1647.7% YoY
Free Cash Flow
-$3.7M
+80.4% YoY
Revenue Growth
+0.0%
EPS Growth
+62.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -228K | 0 | 0 | -235K | 0 |
| Operating Income | -48M | -54M | -51M | -44M | -29M |
| EBITDA | -48M | -34M | -26M | -21M | -11M |
| Net Income | -23M | -34M | -26M | 757K | -12M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37M | 25M | 30M | 42M | 55M |
| Total Assets | 48M | 30M | 35M | 50M | 59M |
| Total Liabilities | 14M | 11M | 11M | 10M | 8M |
| Shareholder Equity | 34M | 19M | 24M | 40M | 51M |
| Total Debt | 638K | 814K | 1M | 1M | 0 |
| Net Debt | -36M | -24M | -29M | -40M | -55M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+80.4% YoY
Capital Expenditures
27K
+84.2% YoY
Free Cash Flow
4M
+80.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-104.3%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.